ArticleFrontiers in aging neuroscience2026
Joint effects of leukocyte-albumin ratio and hypertension are associated with multidimensional cognitive decline and Alzheimer's disease risk in older adults: evidence from NHANES and a clinical AD validation cohort.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alzheimer's disease (AD) pathogenesis involves complex interactions between neuroinflammation and vascular dysfunction. While leukocyte-albumin ratio (LAR) and hypertension are independently linked to cognitive decline, their joint associations with multidimensional cognitive impairment and AD risk remain understudied. Methods: We analyzed two cohorts: 1,300 adults (≥ 60 years) from NHANES 2011-2014, and a clinical cohort (50 AD patients + 125 age-/gender-matched controls). LAR was calculated, hypertension was defined as per JNC7 criteria, and cognitive function was assessed via AD-sensitive tests standardized to Results: In the NHANES cohort, LAR was significantly correlated with DSST performance; participants with co-occurring high LAR + hypertension had lower scores across three cognitive domains, with age- (65-74 years) and sex-specific patterns and a 2.17-fold higher all-cause mortality risk. In the validation cohort, AD patients had higher LAR, with the highest LAR quartile linked to a 3.92-fold increased AD risk ( Conclusion: Our findings support an association between LAR, hypertension, and cognitive decline. Elevated LAR in conjunction with hypertension is associated with poorer cognitive performance across multiple domains in older adults, as observed in both the NHANES and a clinical AD cohort. As a low-cost, easily measurable biomarker, LAR may hold promise for early AD risk stratification in primary care, highlighting a potential target for combined anti-inflammatory and antihypertensive interventions. However, its modest discriminative ability (AUC = 0.61) indicates that LAR should not be used as a standalone diagnostic tool. Prospective longitudinal studies are warranted to validate these associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.